With a total of 21.4 billion units in the first year, what is the impact of centralized insulin proc

It has a certain impact on saving medical costs, after all, the market demand for diabetes drugs is huge. The market size of diabetes drugs is expected to exceed 100 billion yuan. Centralized insulin collection can result in significant savings in medical costs.

Among them, the batch of insulin centralized procurement in Anhui Province medical institutions in the first year of the agreement volume of about 10,000 copies, annual cost savings of 100 million yuan; He said that the implementation of the results of this selection will greatly reduce the burden on patients.

It has an impact on the largest hypoglycemic drug in the Chinese market. As the only hormone in the body that lowers blood sugar, it also promotes glycogen, fat, and protein synthesis. In fact, centralized insulin procurement is already in the pipeline, and the official has "revealed" the centralized procurement of insulin.

Related news, industry sources said that the Medical Insurance Bureau, the Procurement Division, and representatives of the Joint Procurement Office of 11 provinces and cities jointly held a centralized drug procurement meeting in Nanjing.

It has a certain impact on safety and efficacy, but it is also higher, and it is a mainstream product in first-tier cities. At the grassroots level, some patients choose to use relatively cheap ones for ** reasons, regardless of the efficacy of the drug.

First- and second-generation insulin. According to the implementation of centralized insulin procurement, Tonghua Dongbao won the bid for 5 products, including mealtime human insulin and basic human insulin; The pharmaceutical industry won the bid for 6 products, including premixed human insulin and prandial insulin analogues; Zhuhai Joint Laboratory won the bid for 6 products of mealtime human insulin, basic human insulin and premixed human insulin. In addition, Wanbang Biochemical, Tianmai Biotech, Hisun Pharmaceutical, and Dongyang Sunshine also won the bid for different products.

It is important to know that insulin drugs work to lower blood sugar through exogenous insulin supplementation. People with type diabetes need to rely on insulin to stay alive, so they must use insulin**; People with type diabetes don't need to rely on insulin to stay alive, but oral administration can lower blood sugar. When medications are ineffective or oral medications are contraindicated, insulin is still needed to control hyperglycemia and reduce the risk of diabetes complications.

Insulin is the most widely marketed hypoglycemic drug in China.

In this case, the cost of insulin will be reduced, and it will be reduced, which can save a lot of medical costs, which is a benefit for patients with diabetes or other insulin drugs, and a very good opportunity for pharmaceutical companies and some mass patients.

There are more than 100 million diabetic patients in China, which is a fairly large population. Diabetes mellitus is a blood sugar abnormality caused by insulin deficiency or insulin resistance, which can be divided into type 1 diabetes and type 2 diabetes. At present, the most important way for people with diabetes in China is to inject insulin or oral hypoglycemic drugs, and this method is a great economic burden for many people, so many people will not take insulin injection if they are not tolerable, which poses a serious threat to people's lives.

Then the policy of China's special centralized procurement of insulin will bring very good benefits to more than 100 million patients in China, the price of insulin will be greatly reduced, and more and more people can afford to treat the disease.

Diabetes itself does not have much impact on the human body, but other complications caused by diabetes, such as uremia, can threaten people's lives, so once diabetes is detected, it is necessary to take immediate measures**. Many Chinese have the problem of unhealthy diet, which is also the main factor that induces diabetes, so there are many people with diabetes in China.

Insulin is a hormone secreted by the body's pancreatic B cells, it is the only hormone in the human body that can play a role in lowering blood sugar, once the deficiency will make the body's blood sugar at a level that cannot be lowered. In many animals, there is also a pancreas that can secrete insulin, so the earliest ** for diabetes is to isolate insulin from cattle.

However, the amount of insulin in the animal is relatively small, and this method is difficult to operate. Later, with the development of molecular biology, people also discovered the chemical nature of insulin, and used some biological methods to artificially produce insulin. Nowadays, there are many manufacturers that produce different brands of insulin, and patients are likely to become dependent on this brand after using it, so if patients who change the brand of insulin may experience discomfort, how to solve this problem remains to be studied.

It will affect the lives of his predecessors, improve their quality of life, allow their bodies to be better protected, prevent diseases, and better perform disease treatment.

Many patients in our country can get better**, no longer suffer from diabetes, and can also reduce the financial pressure on their medication.

Diabetes mellitus is one of the most common metabolic diseases with abnormal blood sugar levels in China, and the occurrence of diabetes is caused by insufficient or non-secretion of insulin and resistance to insulin, among which the number of patients with diabetes caused by insufficient insulin secretion is the largest. Therefore, the most effective measure for diabetes is to inject insulin to lower blood sugar. Although there are differences between different brands of insulin, it is generally a relatively high level, which has caused a more serious burden on many patients, so China began to implement insulin centralized procurement measures, and after the full implementation of this measure, the average ** decline has reached 48%, so why is the ** fluctuation so big?

This is because the centralized procurement of insulin is made by the state to buy insulin in large quantities, which is equivalent to the highest insulin, and will negotiate with relevant brands, so it can strive for the largest price and reduce the burden on patients. Nowadays, many diabetic patients in China will choose whether to inject insulin premature fibrillation according to the degree of their condition, and if they do not reach a level that seriously affects their lives, they will not choose to inject insulin, which will cause serious damage to other organs of the human body in the long run.

Therefore, insulin needs to be injected for a long time, and the implementation of this policy will help patients maintain the continuity of medication. Insulin is the only hormone in the body that can lower blood sugar levels, so once deficient, the body's blood sugar levels will be in a high and uncontrollable state, and diabetes will occur.

Now the most effective measure for diabetes is insulin injection, insulin is now synthesized after people's research, compared with the beginning, ** has been in a downward trend. However, there is also a situation where different brands of insulin have different effects on different patients, and patients may not be suitable if they change insulin, so many people may still have difficulty in taking drugs.

Because there will be professionals to negotiate for us, they will use the market prospect as the basis for negotiation, and talk about the lowest level of drugs.

Because the technology is mature and can be mass-produced, the ** fluctuation is relatively large.

It is because the state has allocated a ** to support this cause, in order to reduce the burden of the people, so the ** has dropped so much.

Shanghai Pharmaceutical Sunshine Procurement Network issued the "Notice on Doing a Good Job in the Sixth Batch of Centralized Procurement of Drugs in the City Organized by the State", announcing that Shanghai will implement the results of the sixth batch of national centralized procurement of Zen and filial piety from now on. Up to now, 31 provinces across the country have implemented centralized insulin procurement, which is expected to save about 9 billion yuan in insulin costs every year after centralized procurement, and will further reduce the drug burden of more than 10 million patients who need long-term or even lifelong insulin injections. This news is undoubtedly great news for people who need insulin, with an average price reduction of 48%, what is this concept?

It's equivalent to buying two pills for the same amount of money. For patients, it's just spring coming. In addition to the happiness of patients, there is a lot of news worth paying attention to, that is, what changes will occur in this 100-billion-level market?

Let's analyze this topic together. <>

Judging from the news this time, the special collection varieties of insulin include the mainstream second and third generations, and the insulin collection varieties are divided into a total of 6 procurement groups, such as meal human insulin, basic human insulin and premixed human insulin. And 11 companies were also selected, so the question is, will these 11 companies carve up the 100 billion market? I think so.

After all, from the perspective of the competitive landscape, the fierce competition in this market is quite exaggerated, and the demand for diabetes drugs in China is particularly large. <>

This has led to the fierce competition in the market, and this time the insulin collection has been fully implemented and the price has been directly reduced, and 48% of the measures will make this 100 billion level market undergo earth-shaking changes. Personally, I don't think it will bring the economy down, but it will also increase consumption in this area. It is very likely that it will not be a 100-billion-level market, but a trillion-level market.

But no matter which aspect you look at, this is a very good introduction for patients, and I think such a policy is also very beneficial. <>

The price reduction of this centralized procurement is larger, which will help domestic leading enterprises seize the market, and the industry competition pattern is expected to be optimized. The successful centralized procurement of insulin marks that China has officially entered the stage of biological drug collection.

I think that if we do this, it will lead to a very significant change in the market, after all, the impact of these insulins on diabetics is very positive, and there are also gods that are beneficial to their health will also strengthen the prevention and treatment of diabetes.